“Global Pulmonary/Respiratory Drug Delivery market set to grow to $62bn by 2024” says new Visiongain report

29 May 2019
Pharma

Visiongain has launched a new pharma report Global Pulmonary/Respiratory Drug Delivery Market Forecast 2019-2029: Suspension Aerosol, Solution Aerosol, Dry Powder Formulation, Metered Dose Inhalers (MDIS), Dry Powder Inhalers (DPIS), Nebulizers, Accessories, Plain Canister, Coated Canister, Asthma, COPD, Cystic Fibrosis, Other Applications, Hospitals & Clinics, Homecare Settings.

The global pulmonary/respiratory drug delivery market reached $40.67 bn in 2018 and is expected to grow at a CAGR of 7.60% in 2019-2024. The MDIs segment is estimated to hold a share of 62.4% in 2018. Increasing prevalence and incidence of chronic respiratory diseases is a major factor that is expected to drive the growth of this market.

The lead analyst of the report commented "Technological advances in drug delivery will have a positive impact on the market for pulmonary drug delivery devices. These advances include the electronic dose counter MDI, incorporation of agglomerated vesicle technology, and technology for supercritical fluids. Moreover, increasing demand for advanced drug delivery devices, improving healthcare infrastructure, ease of use, and increase in healthcare spending are some of the major factors that will provide lucrative opportunities in the near future."

Leading companies featured in the report include AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Novartis AG, OMRON Corporation, Sunovion Pharmaceuticals Inc., Teva and other companies

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever